Expert Q&As
Launching in EU - Q&A 8
What risk areas should we pay special attention to (pharmacovigilance, legal, compliance, etc.) when launching in Europe?
Access decades of experience
What’s Inside the Q&A:
Pharmacovigilance Systems
Uncover how Europe’s safety oversight demands transform the way you monitor, report, and protect patient outcomes.
Legal and Liability Frameworks
Explore the intersecting layers of EU law that reshape your approach to contracts, privacy, and product responsibility.
Compliance and Ethics Culture
See how embedding transparency and integrity from day one becomes your strongest shield against regulatory risk.
Reputation and Risk Management
Learn how strategic communication and preparedness safeguard both your market access and public trust.
Download our expert answer
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 8
What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?
Expert Q&As
First interactions with EMA - Q&A 3
Why is early engagement with EMA, payers, KOLs, and patient groups so important?
Expert Q&As
First interactions with EMA - Q&A 6
What CMC (Chemistry, Manufacturing, and Controls) expectations in the EU might surprise biopharma companies?
